Intellia Therapeutics Inc (NTLA) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $14.28
• Market Cap: $1.55B
• EPS: $-4.25
• 52-Week High: $28.25
• 52-Week Low: $5.90

Market Sentiment

Intellia Therapeutics Inc currently has a Bullish sentiment score of 0.24.

About Intellia Therapeutics Inc

Intellia Therapeutics, Inc. (NTLA) is a pioneering gene editing company based in Cambridge, Massachusetts, specializing in the development of transformative therapies for genetic disorders using its proprietary CRISPR/Cas9 technology. The company is advancing a diverse pipeline of innovative treatment candidates currently in clinical trials, underscoring its commitment to precision medicine. As a frontrunner in the gene editing landscape, Intellia benefits from a strong intellectual property ...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Intellia Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does NTLA pay dividends?

Intellia Therapeutics Inc (NTLA) does not currently pay a regular dividend.

What is NTLA's market cap?

Intellia Therapeutics Inc (NTLA) has a market capitalization of $1.55B with a current stock price of $14.28.